The latest update is out from Cassava Sciences ( (SAVA) ). Cassava Sciences has settled with the SEC over allegations of misleading statements related to its Alzheimer's drug trial, agreeing to a $40 million penalty while not admitting wrongdoing. The settlement, awaiting court approval, also involves two former employees and comes with a permanent injunction against future violations. Cassava has since taken steps to bolster corporate governance and is focusing on ongoing Phase 3 trials, with a hopeful outlook for its drug simufilam's potential to aid Alzheimer's patients.